Distributed via the HAN Info ServiceFebruary 09, 2012, 15:00 ESTCDCHAN-00324-ADV-N
A recent review of randomized clinical trial data for the influenza neuraminidase inhibitor antiviral medications, and two related commentaries, raised questions about the value of antiviral medications for the prevention and treatment of influenza. On February 7, 2012, the Centers for Disease Control and Prevention (CDC) posted a “Have You Heard?” piece in response. The CDC response states “After careful consideration of all available evidence, CDC guidance on the use of antiviral medications remains unchanged.” CDC continues to recommend the use of neuraminidase inhibitor antiviral drugs (oral oseltamivir and inhaled zanamivir) as an important adjunct in the prevention and treatment of influenza.
These recommendations emphasize early antiviral treatment as soon as possible for patients who are severely ill and for those who are at greatest risk for complications from influenza.
Patients who should receive early antiviral treatment include:
CDC estimates that influenza virus infections in the United States result in an average of more than 200,000 related hospitalizations and 3,300–49,000 deaths each year, depending upon the severity of the influenza season. Annual influenza vaccination of all persons aged 6 months and older is recommended, and is the best way to prevent influenza. However, available evidence for seasonal influenza and 2009 pandemic H1N1 consistently indicates that antiviral treatment, when initiated as soon as possible, can have clinical and public health benefit in reducing severe outcomes of influenza. Therefore, neuraminidase inhibitor antiviral medications continue to be recommended for treatment of influenza.
The full CDC response is available at: www.cdc.gov/media/haveyouheard/stories/Influenza_antiviral.html.
For a summary of CDC antiviral guidance for the 2011-2012 influenza season see: www.cdc.gov/flu/pdf/professionals/antivirals/clinician-antivirals-2011.pdf.
For the full document outlining ACIP and CDC recommendations and references supporting the statements in the “Have You Heard,” CDC response, see “Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)” at: www.cdc.gov/mmwr/pdf/rr/rr6001.pdf.
To read the review of randomized clinical trial data for the influenza neuraminidase inhibitor antiviral medications and related commentaries, see:
1300 Wilson Boulevard | Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2013 Infectious Diseases Society of America